GPVI is also a novel antiplatelet target for the treatment of inflammatory disorders including CAD (reviewed in36,38,39), and levels of membrane bound and soluble GPVI predict outcomes after myocardial infarction and stroke (reviewed in40). This evidence concerns the gene GP6 and stroke disorder.